Alfred E. Tiefenbacher GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alfred E. Tiefenbacher GmbH & Co KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10543
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alfred E. Tiefenbacher GmbH & Co KG (AET) is an independent pharmaceutical company that focuses on the development of active pharmaceuticals ingredients. It offers products in the forms of tablets, capsules, oral solution, patches, long acting injectables, ophthalmic solution and inhaled therapies. The company develops and supply finished dosage form (FDF) generic pharmaceuticals to marketing organizations internationally. AET also provides services such as active pharmaceutical ingredient (API) sourcing; clinical trials; quality assurance; registration; supply chain; marketing and sales; and intellectual property services. The company operates in India, Cyprus, Malta, China and the US. AET is headquartered in Hamburg, Germany.

Alfred E. Tiefenbacher GmbH & Co KG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Alfred E. Tiefenbacher Receives Technology of Pramipexole from Hyundai Pharmaceutical 10
Alfred E. Tiefenbacher Forms Joint Venture with Combino Pharm 11
AET BioTechnologie Enters Into Co-Development Agreement With BioXpress Therapeutics For Adalimumab Biosimilar 12
Licensing Agreements 13
Hyundai Pharm Enters Into Licensing Agreement With Alfred E. Tiefenbacher For Pramipexole SR 13
Alfred E. Tiefenbacher GmbH & Co KG – Key Competitors 14
Alfred E. Tiefenbacher GmbH & Co KG – Key Employees 15
Alfred E. Tiefenbacher GmbH & Co KG – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Joint Venture 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Key Facts 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfred E. Tiefenbacher GmbH & Co KG, Deals By Therapy Area, 2012 to YTD 2018 8
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Alfred E. Tiefenbacher Receives Technology of Pramipexole from Hyundai Pharmaceutical 10
Alfred E. Tiefenbacher Forms Joint Venture with Combino Pharm 11
AET BioTechnologie Enters Into Co-Development Agreement With BioXpress Therapeutics For Adalimumab Biosimilar 12
Hyundai Pharm Enters Into Licensing Agreement With Alfred E. Tiefenbacher For Pramipexole SR 13
Alfred E. Tiefenbacher GmbH & Co KG, Key Competitors 14
Alfred E. Tiefenbacher GmbH & Co KG, Key Employees 15
Alfred E. Tiefenbacher GmbH & Co KG, Other Locations 16
Alfred E. Tiefenbacher GmbH & Co KG, Subsidiaries 16
Alfred E. Tiefenbacher GmbH & Co KG, Joint Venture 16

List of Figures
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfred E. Tiefenbacher GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Alfred E. Tiefenbacher GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PT Garuda Indonesia (Persero) Tbk:企業の戦略・SWOT・財務情報
    PT Garuda Indonesia (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Garuda Indonesia (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Puma SE (PUM):企業の財務・戦略的SWOT分析
    Puma SE (PUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Banco Popular Espanol, S.A.:戦略・SWOT・企業財務分析
    Banco Popular Espanol, S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Popular Espanol, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Green Cross Holdings Corp (005250):企業の財務・戦略的SWOT分析
    Summary Green Cross Holdings Corp (Green Cross) is a developer and manufacturer of pediatric and adult vaccines against infectious diseases. The company’s products comprise specialty medicines, general medicines, health functional foods, products for infants and toddlers, cosmetics, quasi drugs and …
  • Aurinia Pharmaceuticals Inc (AUP):企業の財務・戦略的SWOT分析
    Summary Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals), formerly known as Isotechnika Pharma Inc, develops and commercialization of therapies. The company pipeline product Voclosporin, is used for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS); and voclos …
  • Cboe Global Markets, Inc (CBOE):企業の財務・戦略的SWOT分析
    Cboe Global Markets, Inc (CBOE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • The Japan Steel Works Ltd:企業の戦略・SWOT・財務情報
    The Japan Steel Works Ltd - Strategy, SWOT and Corporate Finance Report Summary The Japan Steel Works Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Exiqon AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Exiqon AS (Exiqon), a subsidiary of Qiagen NV, is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company provides product categories such as microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reag …
  • bluebird bio Inc (BLUE):製薬・医療:M&Aディール及び事業提携情報
    Summary Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immuno …
  • Credicorp Ltd (BAP):企業の財務・戦略的SWOT分析
    Credicorp Ltd (BAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Dentsply Sirona, Inc.:戦略・SWOT・企業財務分析
    Dentsply Sirona, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dentsply Sirona, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The 77 Bank Ltd:企業の戦略・SWOT・財務情報
    The 77 Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The 77 Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Venus Remedies Ltd (VENUSREM)-製薬・医療分野:企業M&A・提携分析
    Summary Venus Remedies Ltd (Venus) is a pharmaceutical company that develops, manufactures and commercializes research, herbal and generic products. The company manufactures complex formulations for oncology injections, neurology, antiseptic, pain management, anti infectives, oncology lyophilized, l …
  • Jacobs Engineering Group Inc (JEC)-石油・ガス分野:企業M&A・提携分析
    Summary Jacobs Engineering Group Inc. (Jacobs) is a provider of technical professional services. The company offers a diverse range of technical, professional, and construction services to industrial, commercial, and governmental customers across the globe. Its service portfolio includes project; pr …
  • Deluxe Corporation:企業の戦略・SWOT・財務情報
    Deluxe Corporation - Strategy, SWOT and Corporate Finance Report Summary Deluxe Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cleco Corporate Holdings, Llc
    Cleco Corporate Holdings, Llc - Strategy, SWOT and Corporate Finance Report Summary Cleco Corporate Holdings, Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • United Bank Of India:企業の戦略・SWOT・財務分析
    United Bank Of India - Strategy, SWOT and Corporate Finance Report Summary United Bank Of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • PT Dian Swastatika Sentosa Tbk (DSSA):企業の財務・戦略的SWOT分析
    PT Dian Swastatika Sentosa Tbk (DSSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • ValiRx Plc (VAL):企業の財務・戦略的SWOT分析
    Summary ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. It uses GeneICE technology, which enables silencing …
  • Iridex Corp (IRIX):企業の財務・戦略的SWOT分析
    Summary Iridex Corp (Iridex) is a medical device company that manufactures and distributes laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. The company offers products such as lasers, laser delivery devices, glaucoma device …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆